Pasar al contenido principal

DISECCIONANDO LA VIA DE SEÑALIZACION DEL TGF-BETA EN BUSQUEDA DE NUEVAS Y MEJORES DIANAS TERAPEUTICAS PARA EL COLANGIOCARCINOMA

PID2022-141984OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Hepatic Stellate Cells Functional Heterogeneity in Liver Cancer

  • Sererols-Viñas, Laura
  • Garcia-Vicién, Gemma
  • Ruiz-Blázquez, Paloma
  • Lee, Ting-Fang
  • Lee, Youngmin A.
  • Gonzalez-Sanchez, Ester
  • Vaquero, Javier
  • Moles, Anna
  • Filliol, Aveline
  • Affò, Silvia
Hepatic stellate cells (HSCs) are the liver's pericytes, and play key roles in liver homeostasis, regeneration, fibrosis, and cancer. Upon injury, HSCs activate and are the main origin of myofibroblasts and cancer-associated fibroblasts (CAFs) in liver fibrosis and cancer. Primary liver cancer has a grim prognosis, ranking as the third leading cause of cancer-related deaths worldwide, with hepatocellular carcinoma (HCC) being the predominant type, followed by intrahepatic cholangiocarcinoma (iCCA). Moreover, the liver hosts 35% of all metastatic lesions. The distinct spatial distribution and functional roles of HSCs across these malignancies represent a significant challenge for universal therapeutic strategies, requiring a nuanced and tailored understanding of their contributions. This review examines the heterogeneous roles of HSCs in liver cancer, focusing on their spatial localization, dynamic interactions within the tumor microenvironment (TME), and emerging therapeutic opportunities, including strategies to modulate their activity, and harness their potential as targets for antifibrotic and antitumor interventions., S.A. is funded by the RYC2022-036321-I, MCIN/AEI/10.13039/501100011033/FEDER, Project PID2021-124694OA-I00, and The European Union grant agreement 101077312*. This work was also funded, in part, through the NIH/NCI Cancer Center Support Core Grant P30 CA008748 to A.A.F.; Y.A.L. is supported by 1R01DK133512 RSG-22-061-01-MM; A.M. is funded by MCIN/AEI/10.13039/501100011033/FEDER, UE through the project grant PID2021-123652OB-I00 and Pfizer grant #77131383; P.R.B. is funded by Ministerio de Universidades fellowships FPU19/05357. J.V. is funded by AEI, MICIN, through the project grant PID2022-141984OB-I00 and the “Ramon y Cajal” program RYC2021-034121-I.Figures Created in BioRender.*Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Epithelial to Mesenchymal Transition Transcriptional Regulator ZEB1 in Liver Cancer: Oncogenic Roles and Therapeutic Potential

  • Gonzalez-Sanchez, Ester
  • Roldán-Hernández, Carlos Andrés
  • Martín-Ramírez, Ana
  • García-Collado, Lucía
  • Fouassier, Laura
  • Vaquero, Javier
Zinc finger E-box binding homeobox 1 (ZEB1) is a member of the zinc finger homeodomain transcription factor family, with a pivotal role in regulating the epithelial to mesenchymal transition (EMT) process. Increasing evidence suggests that ZEB1 is overexpressed in liver tumors, including hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), and it correlates with advanced disease features and reduced overall survival. Here, we examine ZEB1 molecular functions, regulatory networks and contribution to tumorigenesis. We also discuss the emerging therapeutic strategies and future research directions aimed at targeting the ZEB1 molecular network to improve the outcome of liver cancer patients., This work was supported by Agencia Estatal de Investigación (AEI), Ministry of Science and Innovation (MICIN), Spain, cofounded by FEDER funds/Development Fund—a way to build Europe, grant numbers PID2022-141984OB-I00 and RYC2021-034121-I, and by Fundación Memoria de D. Samuel Solorzano Barruso, grant number FS/14-2023, to J.V. This work was also funded by «Escalera de Excelencia» of the Education Ministry of the Castilla y León autonomous government, plus the European Regional Development Fund (CLU-2023-2-01). J.V. was funded by AEI and MICIN, through the “Ramon y Cajal” program RYC2021-034121-I. C.A.R.-H. was funded by CSIC through a JAE-PRE fellowship (JAEPR23102). L.G.-C. was funded by AEI, MICIN through the PID2022-141984OB-I00 grant. The CIBEREHD, National Biomedical Research Institute on Liver and Gastrointestinal Diseases, is funded by the Instituto de Salud Carlos III, Spain., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

NADPH oxidase 1/4 dual inhibition impairs transforming growth factor-beta protumorigenic effects in cholangiocarcinoma cancer-associated fibroblasts

  • Amengual, Josep
  • Gonzalez-Sanchez, Ester
  • Yáñez-Bartolome, Mariana
  • Sererols-Viñas, Laura
  • Ravichandran, Sriram
  • Guiton, Celia
  • Fuste, Noel P.
  • Alay, Ania
  • Hijazo-Pechero, Sara
  • Martín-Mur, Beatriz
  • Gut, Marta
  • Esteve-Codina, Anna
  • Cantos-Cortes, Ana
  • Espinosa-Sotelo, Rut
  • Ramos, Emilio
  • Serrano, Teresa
  • Calvo, Mariona
  • Laquente, Berta
  • Ferrer, Joana
  • Pons, Gabriel
  • Mendez-Lucas, Andrés
  • Dooley, Steven
  • Ilyas, Sumera I.
  • Vallette, Marie
  • Aoudjehane, Lynda
  • Lequoy, Marie
  • Fouassier, Laura
  • Coulouarn, Cédric
  • Affò, Silvia
  • Scheiter, Alexander
  • Calvisi, Diego F.
  • Tian, Tian V.
  • Fabregat, Isabel
  • Vaquero, Javier
Transforming growth factor beta (TGF-β) signalling has become an attractive therapeutic target due to its pro-tumorigenic actions on epithelial cells and its immunosuppressive effects in the tumour microenvironment. In intrahepatic cholangiocarcinoma (iCCA), a highly aggressive malignancy of the biliary tract with poor prognosis, the latest clinical trials using TGF-β inhibitors have failed indicating that the specific actions carried out by TGF-β in iCCA are yet not well delineated. Here, we show that TGF-β signalling is highly active in iCCA and exerts a prominent suppressor effect on tumour cell lines and organoids established from iCCA metastases biopsies, that relies on a functional canonical SMAD2/3/4 signalling. Thus, TGF-β inhibitors promote, instead of inhibiting, tumour cell growth. In this context, a promising strategy is to target intracellular proteins downstream the TGF-β receptors accounting only for TGF-β pro-tumorigenic actions. NADPH oxidase 4 (NOX4), a downstream mediator of the TGF-β signalling pathway, is strictly expressed in cancer-associated fibroblasts (CAF) of iCCA and acts in concert with NOX1 to regulate CAF functions. Use of a dual NOX4/NOX1 inhibitor impaired CAF actions and reduced tumour growth in vitro and in two different in vivo iCCA experimental models. Collectively, our findings reveal an actionable way to specifically target TGF-β pro-tumorigenic actions in CAF from iCCA without undesirable side effects on tumour cells, suggesting a potentially bright future for dual NOX4/NOX1 inhibitors in the clinics, alone or in combination with other therapies., This work was supported by (i) Spanish Association for Cancer Research (AECC), Spain, grant #PRYGN211279FABR, to I.F.; (ii) Agencia Estatal de Investigación (AEI), Ministry of Science and Innovation (MICIN), Spain, cofounded by FEDER funds/Development Fund—a way to build Europe, grant numbers #RTI2018-094079-B-100, #RTC2019-007125-1, to I.F.; #PID2019-108651RJ-I00, PID2022-141984OB-I00 and RYC2021-034121-I, to J.V. J.V. was funded by AEI, MICIN, through the Retos Investigación grant number PID2019-108651RJ-I00/DOI 10.13039/501100011033 and “Ramon y Cajal” program RYC2021-034121-I. The CIBEREHD, National Biomedical Research Institute on Liver and Gastrointestinal Diseases, is funded by the Instituto de Salud Carlos III, Spain. We thank the CERCA Programme/Generalitat de Catalunya for institutional support. Institutional support to CNAG was provided by the Spanish Ministry of Science and Innovation through the Instituto de Salud Carlos III, and by the Generalitat de Catalunya through the Departament de Salut and the Departament de Recerca i Universitats. C.C. is supported by Inserm, Université de Rennes, Ligue Contre le Cancer (R23037NN), INCa (EU TRANSCAN23-002-2023-129, INCa_18688, R21251ND), ITMO Cancer of AVIESAN within the framework of the 2021-2030 Cancer Control Strategy, on funds administered by Inserm (C18007NS, C20013NS, C20014NS), the French Ministry of Health and the French National Cancer Institute (PRT-K20-136). T.V.T. was supported by grants from the Spanish Ministry of Science, Innovation and University (PID2019-108008RJ-I00, PID2023-146827OB-I00), Fundació La Marató TV3 (201931-31), and “Ramon y Cajal” program (RYC2020-029098-I). L.F. received financial support from the “Ligue contre le cancer” (RS24/75-62) and from ITMO Cancer of Aviesan on funds administered by Inserm (C21044DS/ ASC21044DSA). S.A. is supported by PID2021-124694OA-I00, MCIN/AEI/ 10.13039/501100011033 and FEDER Una manera de hacer Europa, The European Union grant agreement 101077312* and Ramon y Cajal program RYC2022-036321-I. *, Peer reviewed